Haemonetics (HAE) Misses Q4 EPS by 5c; Guides FY16 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Haemonetics (HAE) Strong Sell Rating Removed at Off Wall Street
April 28, 2015 11:11 AM EDTHaemonetics's (NYSE: HAE) Strong Sell recommendation was removed at Off Wall Street after the company reported Q4 results and guidance, according to sources. Analysts noted FY16 guidance implies revenue and EPS growth.
... MoreBarrington Research Downgrades Haemonetics (HAE) to Market Perform
April 28, 2015 9:38 AM EDTBarrington Research downgraded Haemonetics (NYSE: HAE) from Outperform to Market Perform with a price target of $44.00. The change follows Q4 results and guidance.
Analyst Michael Petusky, "While we like many aspects of the Haemonetics story, particularly longer term, we do not see the... More
Haemonetics (HAE) PT Lifted at Jefferies Despite FX Hit
April 28, 2015 8:38 AM EDTJefferies analyst Anthony Petrone reiterated a Buy rating and bumped his price target on Haemonetics (NYSE: HAE) to $48.00 (from $45.00) following Q4 results. The analyst said while FX was unavoidable the underlying trends support a rebound in FY16.
Petrone commented, "HAE... More
